Drug approval: Selpercatinib and pralsetinib - RET-altered non-small cell lung cancer

被引：0
|
作者：
Courtier, Baudouin [1 ]
Pierret, Thomas [2 ]
机构：
[1] Hop St Louis, Serv Oncol Med, 1 Ave Claude Vellefaux, F-75010 Paris, France
[2] CHU Grenoble Alpes, Oncol Thorac, 1 Blvd Chantourne, F-38700 La Tronche, France
来源：
BULLETIN DU CANCER | 2021年 / 108卷 / 06期
关键词：
Lung cancer; Targeted therapies; RET; Metastases;
D O I：
10.1016/j.bulcan.2021.04.003
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：562 / 563
页数：2
相关论文
共 50 条
  • [1] Drug approval: Selpercatinib and pralsetinib - RET-altered thyroid cancer
    Courtier, Baudouin
    Hadoux, Julien
    [J]. BULLETIN DU CANCER, 2021, 108 (11) : 989 - 991
  • [2] An overview of the role of selpercatinib and pralsetinib in RET-fusion-positive non-small cell lung cancer (NSCLC)
    Nguyen, Vanessa Quang
    Geirnaert, Marc
    [J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, : 450 - 456
  • [3] Rethinking treatment for RET-altered lung and thyroid cancers: selpercatinib approval by the EMA
    Della Corte, C. M.
    Morgillo, F.
    [J]. ESMO OPEN, 2021, 6 (01)
  • [4] Selpercatinib Receives Regular Approval for Non-Small Cell Lung Cancer
    Larkin, Howard D.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 328 (17): : 1679 - 1679
  • [5] Use of Pralsetinib as Neoadjuvant Therapy for Non-Small Cell Lung Cancer Patient With RET Rearrangement
    Zhou, Ning
    Li, Tong
    Liang, Maoli
    Ren, Fan
    Ni, Hong
    Liu, Wei
    Shi, Tao
    Xu, Dongbo
    Chen, Qiusong
    Yu, Haonan
    Song, Zuoqing
    Zu, Lingling
    Li, Shuo
    Xu, Song
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [6] Exposure-Response Relationships for Pralsetinib in Patients with RET-Altered Thyroid Cancer or RET Fusion-Positive Nonsmall Cell Lung Cancer
    Kassir, Nastya
    Mcdougall, David
    Kuruvilla, Denison
    Kim, Sean
    Kumar, Shaun
    Rahman, Ahmadur
    Ruf, Thorsten
    Cheeti, Sravanthi
    Ankrom, Wendy
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 64 (06): : 685 - 696
  • [7] Treatment with pralsetinib (formerly BLU-667), a potent and selective RET inhibitor, provides rapid clearance of ctDNA in patients with RET-altered non-small cell lung cancer (NSCLC) and medullary thyroid cancer (MTC)
    Lee, D. H.
    Subbiah, V.
    Gainor, J. F.
    Taylor, M. H.
    Zhu, V. W.
    Doebele, R. C.
    Lopes, G.
    Baik, C.
    Garralda, E.
    Gadgeel, S. M.
    Kim, D-W.
    Turner, C. D.
    Palmer, M.
    Miller, S.
    Curigliano, G.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [8] Pralsetinib: Treatment of metastatic RET fusion-positive non-small cell lung cancer
    Nguyen, Ly
    Monestime, Shanada
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2022, 79 (07) : 527 - 533
  • [9] Matching-adjusted indirect comparison (MAIC) of treatment outcomes for selective RET inhibitors, selpercatinib and pralsetinib, in non-small cell lung cancer (NSCLC)
    Hochmair, M. J.
    Nadal, E.
    D'yachkova, Y.
    Puri, T.
    Vickers, A.
    Wolowacz, S.
    Wang, X.
    Kiiskinen, U.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S62 - S63
  • [10] Pralsetinib for the treatment of non-small cell lung cancer
    Fu, X-Y
    Dong, X-D
    Zeng, L.
    Ashby, C. R., Jr.
    Chen, Z-S
    Cheng, C.
    [J]. DRUGS OF TODAY, 2021, 57 (09) : 559 - 569
12345